UK Health Minister Links Public Mistrust of Palantir to NHS Data Opt-Outs

A UK health minister has publicly acknowledged that patient distrust of Palantir Technologies is contributing to a rise in NHS data-sharing opt-outs, according to a report by The Next Web. The comments come as the software company’s role in the UK’s health-data infrastructure continues to draw scrutiny from privacy advocates and members of the public.

Palantir, a US-based data-analytics firm best known for its work with government and defence clients, has expanded into healthcare in recent years, including contracts connected to the National Health Service. Its platforms are used to integrate and analyse large datasets, a capability that has proven valuable for health-system planning but has also fuelled concerns about how patient information is handled and who can access it.

According to the report, the minister indicated that mistrust surrounding Palantir’s involvement is prompting patients to exercise their right to opt out of data sharing — a development that could complicate efforts to build comprehensive national health datasets. Widespread opt-outs reduce the completeness of the data available to researchers and planners, potentially limiting the benefits these programmes are designed to deliver.

The tension illustrates a broader challenge for Palantir as it diversifies beyond its defence and intelligence roots. The company, which builds software platforms used by the intelligence community in the United States, the United Kingdom and internationally, has faced recurring public-relations hurdles when entering civilian domains, particularly healthcare, where sensitivity around personal data is high.

For investors tracking the company, the episode underscores the reputational dimension of Palantir’s public-sector expansion. Shares of Palantir Technologies (PLTR) traded at $174.33, down 0.06% from the previous close of $174.43, giving the company a market capitalisation of roughly $439.7 billion. The stock’s flat movement suggests the remarks did not materially affect trading, though ongoing debate over NHS contracts remains a factor for the company’s UK business.

The UK government has defended its use of commercial technology partners as essential to modernising health services, while campaigners continue to press for stronger guarantees on consent and data governance. The minister’s comments suggest that even senior officials recognise the trust deficit as an operational concern, not merely a political one.

What to watch

• Future statements from the UK Department of Health and Social Care on NHS data-platform contracts and patient consent policies.
• Updates on NHS opt-out rates and any measures introduced to improve public confidence in data sharing.
• Palantir’s forthcoming earnings report and any commentary on its UK public-sector business.
• Developments in UK procurement or oversight frameworks affecting commercial data-analytics providers.

Source: original release